This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Stealth BioTherapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
14.4%
Earnings growth rate
62.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 19.7% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide
Jun 01Stealth BioTherapeutics skyrockets on data for elamipretide studies
May 06FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide
Jan 06Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31
Stealth Bio launches $3.2M registered direct offering
Nov 20Revenue & Expenses BreakdownBeta
How Stealth BioTherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -53 | 20 | 27 |
| 30 Sep 21 | 0 | -51 | 20 | 25 |
| 30 Jun 21 | 0 | -56 | 20 | 24 |
| 31 Mar 21 | 0 | -50 | 19 | 26 |
| 31 Dec 20 | 0 | -57 | 19 | 29 |
| 30 Sep 20 | 21 | -35 | 20 | 35 |
| 30 Jun 20 | 21 | -41 | 22 | 38 |
| 31 Mar 20 | 21 | -44 | 23 | 40 |
| 31 Dec 19 | 21 | -72 | 22 | 45 |
| 30 Sep 19 | 0 | -102 | 26 | 45 |
| 30 Jun 19 | 0 | -108 | 25 | 51 |
| 31 Mar 19 | 0 | -120 | 23 | 54 |
| 31 Dec 18 | 0 | -97 | 22 | 53 |
| 30 Sep 18 | 0 | -92 | 16 | 59 |
| 31 Dec 17 | 0 | -83 | 17 | 63 |
Quality Earnings: MITO is currently unprofitable.
Growing Profit Margin: MITO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MITO is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare MITO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: MITO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.